Literature DB >> 19702552

Therapeutic potential of 5-HT7 receptors in mood disorders.

Ouissame Mnie-Filali1, Laura Lambas-Señas, Hélène Scarna, Nasser Haddjeri.   

Abstract

Serotonin (5-HT) exerts its diverse physiological and pharmacological effects through the activation of multiple receptor subtypes. One of the newest members of this family is the 5-HT(7) receptor. Increasing investigations on this receptor are currently undertaken to highlight its physiological and physiopathological significance. With the development of selective 5-HT(7) receptor ligands, preclinical studies have started to elucidate the functions of this receptor subtype in more details. Hence, growing body of evidence suggests that the 5-HT(7) receptor is involved in biological processes such as circadian rhythm and thermoregulation, in addition to disorders in which disturbances of the latter are considered to be an important contributing factor. Moreover, preclinical data support the use of 5-HT(7) receptor antagonism as a promising mechanism for the treatment of several dysfunctions such as cognitive deficits and, importantly, have also unveiled anxiolytic and antidepressant-like properties. In this review, we will report major advances in the discovery of 5-HT(7) receptor roles, with special emphasis on the potential application of their antagonists as novel anxiolytic and antidepressant drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19702552     DOI: 10.2174/138945009789735129

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  11 in total

Review 1.  Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders.

Authors:  Marcello Leopoldo; Enza Lacivita; Francesco Berardi; Roberto Perrone; Peter B Hedlund
Journal:  Pharmacol Ther       Date:  2010-10-20       Impact factor: 12.310

2.  The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses.

Authors:  Eunice Y Yuen; Xiangning Li; Jing Wei; Masakuni Horiguchi; Herbert Y Meltzer; Zhen Yan
Journal:  Mol Pharmacol       Date:  2011-11-09       Impact factor: 4.436

3.  Structural manipulation of aporphines via C10 nitrogenation leads to the identification of new 5-HT7AR ligands.

Authors:  Anupam Karki; Hari K Namballa; Ian Alberts; Wayne W Harding
Journal:  Bioorg Med Chem       Date:  2020-06-05       Impact factor: 3.641

4.  Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy.

Authors:  Ouissame Mnie-Filali; Céline Faure; Laura Lambás-Señas; Mostafa El Mansari; Hassina Belblidia; Elise Gondard; Adeline Etiévant; Hélène Scarna; Anne Didier; Anne Berod; Pierre Blier; Nasser Haddjeri
Journal:  Neuropsychopharmacology       Date:  2011-02-16       Impact factor: 7.853

5.  The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior.

Authors:  Gor Sarkisyan; Amanda J Roberts; Peter B Hedlund
Journal:  Behav Brain Res       Date:  2010-01-25       Impact factor: 3.332

Review 6.  5-HT7 receptor signaling: improved therapeutic strategy in gut disorders.

Authors:  Janice J Kim; Waliul I Khan
Journal:  Front Behav Neurosci       Date:  2014-12-11       Impact factor: 3.558

Review 7.  Cellular mechanisms of the 5-HT7 receptor-mediated signaling.

Authors:  Daria Guseva; Alexander Wirth; Evgeni Ponimaskin
Journal:  Front Behav Neurosci       Date:  2014-10-01       Impact factor: 3.558

Review 8.  Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews.

Authors:  Michele Fornaro; Domenico De Berardis; Giampaolo Perna; Marco Solmi; Nicola Veronese; Laura Orsolini; Elisabetta Filomena Buonaguro; Felice Iasevoli; Cristiano André Köhler; André Ferrer Carvalho; Andrea de Bartolomeis
Journal:  Biomed Res Int       Date:  2017-05-09       Impact factor: 3.411

9.  Microdosing psychedelics: More questions than answers? An overview and suggestions for future research.

Authors:  Kim Pc Kuypers; Livia Ng; David Erritzoe; Gitte M Knudsen; Charles D Nichols; David E Nichols; Luca Pani; Anaïs Soula; David Nutt
Journal:  J Psychopharmacol       Date:  2019-07-14       Impact factor: 4.153

Review 10.  Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients.

Authors:  Vanessa Torres-Llenza; Pooja Lakshmin; Daniel Z Lieberman
Journal:  Neuropsychiatr Dis Treat       Date:  2018-01-11       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.